Treatment of Kaposi's sarcoma by combination of actinomycin-D, vincristine and imidazole carboxamide (NSC-45388): Results of a randomized clinical trial
| Autor: | S. K. Kyalwazi, Raphael Owor, Edward Katongole-Mbidde, Tom Toya, Stephen K. Lwanga, Charles L. Vogel, Charles L. M. Olweny |
|---|---|
| Rok vydání: | 1974 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Tumour regression Vincristine Adolescent Pharmacology law.invention Pharmacotherapy Randomized controlled trial law Internal medicine medicine Humans Uganda Child Sarcoma Kaposi Kaposi's sarcoma Aged Imidazole carboxamide Clinical Trials as Topic business.industry Imidazoles Middle Aged Prognosis medicine.disease Dacarbazine Clinical trial Child Preschool Dactinomycin Drug Therapy Combination Female Sarcoma Triazenes business Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Cancer. 14:649-656 |
| ISSN: | 1097-0215 0020-7136 |
| Popis: | Previous trials at our Institute revealed the effectiveness of actinomycin-D and vincristine in the treatment of Kaposi's Sarcoma. We herein report the results of a further randomized trial designed to test the efficacy of the three-drug combination consisting of actinomycin-D, vincristine and imidazole carboxamide and to compare the results with those obtained by combining actinomycin-D and vincristine only for all forms of Kaposi's Sarcoma. Of the 40 patients treated with two drugs, 22 (55%) achieved complete tumour regression, 13 (32.5%) had partial response and 5 (12.5%) did not respond. On the other hand, 30 out of 32(94%) of those receiving three drugs had complete tumour regression, one had partial and one had no response. There is a significantly higher complete response rate (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text